Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092631 - COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCERS CHARACTERIZED BY EXPRESSION OF MESOTHELIN

Publication Number WO/2020/092631
Publication Date 07.05.2020
International Application No. PCT/US2019/058943
International Filing Date 30.10.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 31/5517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
Applicants
  • FRED HUTCHINSON CANCER RESEARCH CENTER [US]/[US]
Inventors
  • MESHINCHI, Soheil
  • KAEDING, Allison June
  • LE, Quy H.
Agents
  • NOWAK, Thomas S.
Priority Data
62/753,74731.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCERS CHARACTERIZED BY EXPRESSION OF MESOTHELIN
(FR) COMPOSITIONS ET MÉTHODES DE DÉTECTION ET DE TRAITEMENT DE CANCERS CARACTÉRISÉS PAR L'EXPRESSION DE LA MÉSOTHÉLINE
Abstract
(EN)
The disclosure provides compositions and methods for detecting and monitoring myeloid leukemia in a subject. Furthermore, the disclosure provides antibody drug conjugates that specifically target mesothelin and related methods of use in treating cancers, including solid tumors and hematological cancers.
(FR)
La présente invention concerne des compositions et des méthodes de détection et de surveillance d'une leucémie myéloblastique chez un sujet. En outre, l'invention concerne des conjugués anticorps-médicament qui ciblent spécifiquement la mésothéline, ainsi que des méthodes associées d'utilisation dans le traitement de cancers, y compris de tumeurs solides et de cancers hématologiques.
Latest bibliographic data on file with the International Bureau